Trial Profile

A clinical trial of NMS-03592088 for treatment of positive Relapsed or Refractory Acute Myeloid Leukemia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NMS 03592088 (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Nerviano Medical Sciences

Most Recent Events

08 Jul 2023 New trial record
22 Jun 2023 According to a Nerviano Medical Sciences media release, the US FDA has given clearance of IND for NMS-03592088 (NMS-088) for treatment of positive Relapsed or Refractory Acute Myeloid Leukemia. The company will conduct this trial in partnership with renowned medical centers and institutions as part of NMS's global program.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com